The role of ovarian ablation in the adjuvant therapy of breast cancer

Sing Huang Tan, Antonio C. Wolff

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Increasing interest has emerged in the role of ovarian function suppression, which has shown equivalence to adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil), whether achieved by surgery or irradiation, in breast cancer patients. Studies have suggested temporary amenorrhea can confer benefit in early breast cancer, giving luteinizing hormone-releasing hormone (LH-RH) agonists an advantage over oophorectomy or radiation. Compared with no therapy, LH-RH agonists reduce risks of recurrence and death among women younger than 50 years of age who have hormone receptor-positive tumors. Trials are assessing the benefits of adding LH-RH agonists to aromatase inhibitors, tamoxifen, or after chemotherapy in women remaining premenopausal, and the necessity for adjuvant chemotherapy with combined ovarian ablation and antiestrogen therapy.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalCurrent oncology reports
Issue number1
StatePublished - Jan 2008

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'The role of ovarian ablation in the adjuvant therapy of breast cancer'. Together they form a unique fingerprint.

Cite this